secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282613
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q3 net loss $45.1M; cash $419M; NVD200 on track for Q1 2023 trial
-------------------------------------------------------------------------

- Net loss of $45.1M ($0.42 per share) vs $60.4M ($0.98) in Q3 2021; R&D expenses fell to $34.1M from $49.4M.
- Cash, cash equivalents and marketable securities of $419M as of Sept 30, 2022; expected runway into Q2 2024.
- NVD200 combination antibody candidate progressing toward clinical trial start in Q1 2023; demonstrated potent in vitro neutralization against Omicron sublineages.
- David Hering named permanent CEO in July; Fred Driscoll appointed interim CFO and Christine Lindenboom to board in October.
- Entered Platform Transfer Agreement with Adimab and signed 9,600 sq ft lease in Newton, MA for expanded lab space.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/0001193125-22-282613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312522282613/d407741d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer